SMLEREVISE

Chronic Hepatitis C Virus infection

Medically Reviewed by Dr. M. Salar Raza | Official SCFHS 2026 Blueprint

Clinical Pathway

Chronic Hepatitis C Virus (HCV) infection is a persistent inflammatory condition of the liver caused by the hepatitis C virus, defined by the presence of detectable HCV RNA for at least six months. This long-term infection can progressively lead to significant liver damage, including fibrosis, cirrhosis, and hepatocellular carcinoma. Current treatment primarily involves direct-acting antiviral (DAA) medications, which are highly effective oral regimens targeting specific viral proteins to inhibit HCV replication. These therapies typically achieve a sustained virologic response (SVR) in over 95% of patients, effectively curing the infection. Treatment duration usually ranges from 8 to 12 weeks, depending on the specific regimen and patient factors. Chronic HCV infection is often asymptomatic for many years, leading to a silent progression of liver disease. When symptoms do appear, they are often non-specific, such as fatigue, malaise, nausea, and right upper quadrant discomfort. As the disease advances to cirrhosis, signs of liver decompensation may emerge, including jaundice, ascites, peripheral edema, spider angiomata, and hepatic encephalopathy.

Clinical Reasoning

The hepatitis C virus is an RNA virus that primarily infects hepatocytes. Upon entry, the virus replicates within the host cells, triggering both innate and adaptive immune responses. In chronic infection, the immune system fails to clear the virus, leading to ongoing hepatocyte damage, inflammation, oxidative stress, and the accumulation of extracellular matrix proteins, which drives progressive hepatic fibrosis. With the advent of modern DAA therapies, the prognosis for chronic HCV infection is excellent, with the vast majority of patients achieving a cure and preventing further liver damage. For those with established cirrhosis, successful treatment can halt disease progression, improve liver function, and significantly reduce the risk of hepatocellular carcinoma, although continued surveillance for cancer may still be necessary. Intravenous drug use (sharing needles, syringes, or drug paraphernalia),Transfusion of blood or blood products before 1992 (when universal screening began),Unsterile tattooing or body piercing practices,Sharing personal care items (e.g., razors, toothbrushes) contaminated with blood,Occupational exposure to blood (e.g., healthcare workers needlestick injuries),Being born to an HCV-infected mother

Sample MCQ

A patient with decompensated cirrhosis secondary to chronic Hepatitis C virus infection presents with persistent, recurrent ascites requiring frequent large-volume paracentesis for symptom management. What is the appropriate dietary advice?

  • ADietary protein restriction to less than 0.8 g/kg per day
  • BDietary fat restriction to less than 20% of total daily calories
  • CUniversal fluid restriction to less than 1 liter per day
  • DDietary sodium restriction to less than 2 grams (88 mmol) per day

Correct Answer: D

### TLDR For patients with decompensated cirrhosis and recurrent ascites, dietary sodium restriction is the cornerstone of management. This approach directly combats fluid retention, which is driven by sodium accumulation, and significantly enhances the efficacy of diuretic therapy. ### Comparison Table | Option | Mechanism | Clinical Nuance | Key Distinction | | :----- | :-------- | :-------------- | :---------------- | | Dietary protein restriction to less than 0.8 g/kg per day | Reduces ammonia production; historically for encephalopathy. | Not recommended for chronic HE; worsens malnutrition in cirrhosis. | Malnutrition risk high; not for ascites treatment. | | Dietary fat restriction to less than 20% of total daily calories | Limits fat intake; may address steatorrhea or hyperlipidemia. | Not primary for ascites management; malnutrition concern in cirrhosis. | Unrelated to ascites pathophysiology. | | Universal fluid restriction to less than 1 liter per day | Decreases total body water; reduces dilutional hyponatremia. | Only for severe hyponatremia (Na<120-125); not routine for ascites. | Sodium is the primary driver of ascites, not free water. | | **Dietary sodium restriction to less than 2 grams (88 mmol) per day** | **Reduces total body sodium, decreasing water retention and ascites.** | **Cornerstone of ascites management; enhances diuretic efficacy.** | **Directly targets fluid retention in cirrhosis.** | ### Detailed Breakdown The correct answer is **Dietary sodium restriction to less than 2 grams (88 mmol) per day**. This is the most crucial dietary intervention for managing ascites in patients with decompensated cirrhosis. In cirrhosis, portal hypertension and splanchnic vasodilation lead to effective arterial hypovolemia, activating the renin-angiotensin-aldosterone system and sympathetic nervous system. This results in renal retention of sodium and water, leading to ascites formation. Limiting dietary sodium directly reduces the total body sodium load, thereby decreasing water retention and the accumulation of ascetic fluid. This strategy significantly improves the effectiveness of diuretic therapy, allowing for better ascites control and reducing the need for frequent large-volume paracentesis. Let's consider why the other options are less appropriate: * **Dietary protein restriction to less than 0.8 g/kg per day:** While protein restriction was historically used for hepatic encephalopathy (HE), current guidelines generally advise against it. Patients with cirrhosis are often malnourished, and protein restriction can exacerbate this, worsening muscle wasting and overall prognosis. Most patients with HE can tolerate a normal or even high-protein diet (1.2-1.5 g/kg/day), with treatment focusing on lactulose and rifaximin. It is not a primary treatment for ascites. * **Dietary fat restriction to less than 20% of total daily calories:** Restricting dietary fat is not a primary intervention for ascites. While some patients with advanced liver disease may experience fat malabsorption due to cholestasis, a blanket fat restriction isn't indicated for ascites management and could contribute to malnutrition. * **Universal fluid restriction to less than 1 liter per day:** Fluid restriction is generally *not* recommended for the routine management of ascites. It is primarily reserved for patients with severe dilutional hyponatremia (typically serum sodium <120-125 mmol/L) to prevent further drops in serum sodium concentration. In the absence of severe hyponatremia, fluid restriction offers little benefit in ascites control and can be challenging for patients, impairing quality of life without significant clinical advantage over sodium restriction and diuretics. Sodium, not free water, is the main driver of ascites.

Master the 2026 SMLE

Explore more clinical protocols in the SMLEREVISE Clinical Knowledge Library.

Try the QBank & Scaled Mocks